Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022

Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022

ABSTRACT Eravacycline is a synthetic fluorocycline approved by the U.S. Food and Drug Administration in 2018. This study aimed to describe clinical and microbiological outcomes in addition to associated adverse effects of eravacycline used in U.S. hospitals. Real-world, observational study involving...

Full description

Bibliographic Details
Main Authors: Ashlan J. Kunz Coyne, Sara Alosaimy, Kristen Lucas, Abdalhamid M. Lagnf, Taylor Morrisette, Kyle C. Molina, Alaina DeKerlegand, Melanie Rae Schrack, S. Lena Kang-Birken, Athena L.V. Hobbs, Jazmin Agee, Nicholson B. Perkins, Mark Biagi, Michael Pierce, James Truong, Justin Andrade, Jeannette Bouchard, Tristan Gore, Madeline A. King, Benjamin M. Pullinger, Kimberly C. Claeys, Shelbye Herbin, Reese Cosimi, Serina Tart, Michael P. Veve, Bruce M. Jones, Leonor M. Rojas, Amy K. Feehan, Marco R. Scipione, Jing J. Zhao, Paige Witucki, Michael J. Rybak
Format: Article
Language:English
Published: American Society for Microbiology 2024-01-01
Series:Microbiology Spectrum
Subjects:
eravacycline
multidrug-resistant
antimicrobial stewardship
Online Access:https://journals.asm.org/doi/10.1128/spectrum.02351-23

Internet

https://journals.asm.org/doi/10.1128/spectrum.02351-23

Similar Items